# GCP & Pharmacovigilance Compliance Symposium - D2S02 - Clinical Trials Post-Pandemic

These presentations examined pandemic 'regulatory flexes' and forced changes to clinical trial operations, contrasting them with pre-pandemic activities. This session covered inspection changes during and after the pandemic, including the introduction of Compliance Readiness Inspections (CRIs) with case studies. Innovations in clinical trial assessments during the pandemic were discussed, along with field investigator observations of post-pandemic clinical research impacts. The modern FDA approach to sponsor, clinical investigator, and clinical bioequivalence inspections was outlined to demonstrate regulatory evolution.

- Kind: Talk
- Year: 2025
- Runtime: 53 min
- By: U.S. Food and Drug Administration
- Archive: [Wikimedia Commons](https://commons.wikimedia.org/wiki/File:GCP_%26_Pharmacovigilance_Compliance_Symposium_-_D2S02_-_Clinical_Trials_Post-Pandemic.webm)
- Licence or status: Public domain (as the archive states it)
- Credit: U.S. Food and Drug Administration
- Who can watch: Teens profiles and older (the archive gives no rating; placed by Invisible Network from its collection and subjects)

[Watch now](https://invisiblenetwork.ai/watch/archive/commons/198199294?play=1)
